AP945A - Encapsulated solution dosage forms of sertraline. - Google Patents

Encapsulated solution dosage forms of sertraline. Download PDF

Info

Publication number
AP945A
AP945A APAP/P/1998/001279A AP9801279A AP945A AP 945 A AP945 A AP 945A AP 9801279 A AP9801279 A AP 9801279A AP 945 A AP945 A AP 945A
Authority
AP
ARIPO
Prior art keywords
sertraline
dosage form
mga
oil
vehicle
Prior art date
Application number
APAP/P/1998/001279A
Other languages
English (en)
Other versions
AP9801279A0 (en
Inventor
William John Curatolo
Ravi Mysore Shanker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP945(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP9801279A0 publication Critical patent/AP9801279A0/xx
Application granted granted Critical
Publication of AP945A publication Critical patent/AP945A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
APAP/P/1998/001279A 1997-07-01 1998-06-25 Encapsulated solution dosage forms of sertraline. AP945A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5140197P 1997-07-01 1997-07-01

Publications (2)

Publication Number Publication Date
AP9801279A0 AP9801279A0 (en) 1998-06-30
AP945A true AP945A (en) 2001-02-28

Family

ID=21971076

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1998/001279A AP945A (en) 1997-07-01 1998-06-25 Encapsulated solution dosage forms of sertraline.

Country Status (40)

Country Link
EP (1) EP0980241B1 (uk)
JP (1) JP3585245B2 (uk)
KR (1) KR100371730B1 (uk)
CN (1) CN1261792A (uk)
AP (1) AP945A (uk)
AR (1) AR015916A1 (uk)
AT (1) ATE256457T1 (uk)
AU (1) AU724635B2 (uk)
BG (1) BG103917A (uk)
BR (1) BR9809712A (uk)
CA (1) CA2290973C (uk)
CO (1) CO4940405A1 (uk)
DE (1) DE69820608T2 (uk)
DK (1) DK0980241T3 (uk)
DZ (1) DZ2544A1 (uk)
EA (1) EA001905B1 (uk)
ES (1) ES2210760T3 (uk)
GT (1) GT199800090A (uk)
HR (1) HRP980378B1 (uk)
HU (1) HUP0002250A3 (uk)
ID (1) ID24673A (uk)
IL (1) IL133075A0 (uk)
IS (1) IS5266A (uk)
MA (1) MA24586A1 (uk)
MY (1) MY119728A (uk)
NO (1) NO996492L (uk)
NZ (1) NZ501252A (uk)
OA (1) OA11246A (uk)
PA (1) PA8454001A1 (uk)
PE (1) PE97299A1 (uk)
PL (1) PL337807A1 (uk)
PT (1) PT980241E (uk)
SK (1) SK282914B6 (uk)
TN (1) TNSN98123A1 (uk)
TR (1) TR199903282T2 (uk)
TW (1) TW382597B (uk)
UA (1) UA68350C2 (uk)
UY (1) UY25070A1 (uk)
WO (1) WO1999001113A1 (uk)
ZA (1) ZA985709B (uk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2346335C (en) * 1998-10-13 2006-04-18 Pfizer Products Inc. Sertraline oral concentrate
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
AU762934B2 (en) 1999-09-03 2003-07-10 Allergan Sales, Llc Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2002017918A2 (en) 2000-08-30 2002-03-07 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
EP1375659A1 (en) * 2002-06-18 2004-01-02 Laboratorio di Diagnostica Moleculare Soluble capsules containing stock mixtures for easy preparation of chemical or biological solutions
AR041745A1 (es) * 2002-10-31 2005-05-26 Alza Corp Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrofobos
WO2016020936A2 (en) * 2014-07-21 2016-02-11 Patel Jayendrakumar Dasharathlal A novel oral gastroretentive pharmaceutical dosage form
CN108014087A (zh) * 2017-12-27 2018-05-11 江苏联环药业股份有限公司 一种盐酸舍曲林胶囊的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009047A1 (en) * 1994-09-19 1996-03-28 The Du Pont Merck Pharmaceutical Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
EP0768083A2 (en) * 1995-07-17 1997-04-16 Pfizer Inc. The use of sertraline to treat post myocardial infarction patients

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009047A1 (en) * 1994-09-19 1996-03-28 The Du Pont Merck Pharmaceutical Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
EP0768083A2 (en) * 1995-07-17 1997-04-16 Pfizer Inc. The use of sertraline to treat post myocardial infarction patients

Also Published As

Publication number Publication date
KR100371730B1 (ko) 2003-02-07
CA2290973C (en) 2003-06-17
EA199900963A1 (ru) 2000-08-28
ES2210760T3 (es) 2004-07-01
IL133075A0 (en) 2001-03-19
TW382597B (en) 2000-02-21
DK0980241T3 (da) 2004-04-05
ATE256457T1 (de) 2004-01-15
HUP0002250A3 (en) 2001-01-29
AP9801279A0 (en) 1998-06-30
TR199903282T2 (xx) 2000-08-21
EP0980241A1 (en) 2000-02-23
NO996492D0 (no) 1999-12-27
PL337807A1 (en) 2000-09-11
HRP980378A2 (en) 1999-04-30
AR015916A1 (es) 2001-05-30
MA24586A1 (fr) 1998-12-31
AU7545098A (en) 1999-01-25
EP0980241B1 (en) 2003-12-17
PA8454001A1 (es) 2000-05-24
JP3585245B2 (ja) 2004-11-04
OA11246A (en) 2002-11-19
KR20010013588A (ko) 2001-02-26
SK282914B6 (sk) 2003-01-09
HRP980378B1 (en) 2001-12-31
CN1261792A (zh) 2000-08-02
BG103917A (bg) 2000-07-31
DE69820608D1 (de) 2004-01-29
SK180599A3 (en) 2001-01-18
ID24673A (id) 2000-07-27
ZA985709B (en) 2000-01-10
PE97299A1 (es) 1999-10-13
DE69820608T2 (de) 2004-12-23
DZ2544A1 (fr) 2003-02-08
MY119728A (en) 2005-07-29
NO996492L (no) 2000-02-29
WO1999001113A1 (en) 1999-01-14
GT199800090A (es) 1999-12-21
UA68350C2 (en) 2004-08-16
BR9809712A (pt) 2000-07-11
TNSN98123A1 (fr) 2005-03-15
JP2000512316A (ja) 2000-09-19
UY25070A1 (es) 2000-12-29
IS5266A (is) 1999-11-23
PT980241E (pt) 2004-03-31
EA001905B1 (ru) 2001-10-22
NZ501252A (en) 2004-11-26
CO4940405A1 (es) 2000-07-24
AU724635B2 (en) 2000-09-28
HUP0002250A2 (hu) 2000-12-28
CA2290973A1 (en) 1999-01-14

Similar Documents

Publication Publication Date Title
US7115565B2 (en) Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US5391377A (en) Biphasic release formations for lipophilic acids
RU2211047C2 (ru) Желатиновые капсулы с твердым покрытием, включающие фармацевтические композиции, практически не содержащие масел
KR102636273B1 (ko) 플로로글루시놀 및 트리메틸플로로글루시놀의 제약 제제
ES2326783T3 (es) Composiciones de n-benzoilestaurosporina espontaneamente dispersables.
JP2002531515A (ja) 水に難溶性の薬剤のための自己乳化組成物
AP945A (en) Encapsulated solution dosage forms of sertraline.
JP2004520398A (ja) 経口生物学的利用能が改善されたパクリタキセルの化学療法マイクロエマルジョン組成物
JPH0840936A (ja) 経口投与薬物のための製剤
US20030133974A1 (en) Encapsulated solution dosage forms of sertraline
US4699776A (en) Suppositories containing analgesics, antipyretics or anti-inflammatory agents
MXPA99012099A (en) Gelatine encapsulated solution dosage forms of sertraline
STRICKLEY et al. Solubilizing vehicles for oral formulation development
JP2022531685A (ja) メチルナルトレキソンの液体経口投与製剤
CZ464299A3 (cs) Želatinové zapouzdření roztokové dávkovači formy sertralinu
AU2922800A (en) Pharmaceutical compositions for oral administration comprising a benzamide and at least an absorption promoter
TW200922637A (en) Pharmaceutical composition with enhanced bioavailability
AU2002249926A1 (en) Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability